Acute Myeloid Leukemia Clinical Trial

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Summary

The primary objective is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid leukemia (AML).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of Acute Myeloid Leukemia
Eighteen years of age or older
Life expectancy of at least 2 months

Exclusion Criteria:

Intracranial disease or epidural disease
Clinically significant cardiac disease
Diabetes mellitus uncontrolled with medication
Pregnant or breast feeding women
Dementia or altered mental status
Known pre-existing clinically significant or uncontrolled disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands
Previous pericarditis
Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea,diarrhea,vomiting

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

34

Study ID:

NCT00279773

Recruitment Status:

Terminated

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

The University of Texas, M.D. Anderson Cancer Center
Houston Texas, 77020, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

34

Study ID:

NCT00279773

Recruitment Status:

Terminated

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider